Wrap Text
Notification of transactions by PDMR and persons closely associated with them
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)
2 June 2017
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Awards under the Company's Short-Term Incentive Scheme
On 1 June 2017, awards over ordinary shares in Mediclinic (the “Shares”) were granted to the following
Directors and other persons discharging managerial responsibilities ("PDMRs") under the rules of the
Company’s Short-Term Incentive (“STI”) Scheme, which was approved by shareholders in December
2015:
Name Director/ PDMR Number of Shares awarded under the
Short Term Incentive Scheme
Danie Meintjes Director 27,187
Jurgens Myburgh Director 10,815
Nil consideration per share was paid for the grant of the awards. The vesting of an award is subject to
employment conditions; no further performance conditions apply.
The following notification made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation relates to the Company’s STI Scheme.
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Daniël Petrus Meintjes
2. Reason for the notification
a) Position / status Chief Executive Officer of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted
transaction under the Company’s Short Term Incentive Scheme
c) Price(s) and
volume(s) Price(s) Volume(s)
Nil cost 27,187
d) Aggregated
information
Aggregated volume 27,187
Price ZAR0.00
e) Date of the 1 June 2017
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Petrus Jurgens Myburgh
2. Reason for the notification
a) Position / status Chief Financial Officer of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted
transaction under the Company’s Short Term Incentive Scheme
c) Price(s) and
volume(s) Price(s) Volume(s)
Nil cost 10,815
d) Aggregated
information
Aggregated volume 10,815
Price ZAR0.00
e) Date of the 1 June 2017
transaction
f) Place of the Johannesburg Stock Exchange
transaction
About Mediclinic International plc
Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South
Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the
quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare
services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-
based private healthcare group.
Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and
2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in
total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1
600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700
inpatient beds in the United Arab Emirates.
During February 2016, the combination of the Company (previously named Al Noor Hospitals Group
plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International
Limited was completed. Mediclinic International Limited was a South African based international private
healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986,
with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai).
The combination resulted in the renaming of the enlarged group to Mediclinic International plc.
Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in
South Africa and the NSX in Namibia.
For further information, please contact:
Capita Company Secretarial Services Limited
Victoria Dalby
+44 (0)207 954 9600
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 02/06/2017 05:01:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
